tiprankstipranks
Trending News
More News >

UBS Increases Stake in Mayne Pharma Group

Story Highlights
UBS Increases Stake in Mayne Pharma Group

Confident Investing Starts Here:

Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.

UBS Group AG and its related bodies corporate have increased their voting power in Mayne Pharma Group Limited, a company in the pharmaceutical industry, from 5.77% to 6.83% as of May 29, 2025. This change in substantial holding reflects UBS’s strategic interest in Mayne Pharma, potentially impacting the company’s market dynamics and signaling a shift in shareholder influence and control.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

YTD Price Performance: -0.40%

Average Trading Volume: 915,341

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$402.2M

For an in-depth examination of MYX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App